Future Industry Expansion | Roadmap
Roadmap — Future Industry ExpansionQSigma360 was architected to allow future exploration of pharmaceuticals, cosmetics, medical devices, chemicals, and dietary supplements. This is roadmap scope only; no finished industry product, complete template set, approved sector workflows, or demo-ready production solution is available for these industries today.
This page describes a future direction only; no complete industry package or demo-ready product is currently available for these industries.
Future expansion may include pharmaceutical manufacturers, cosmetics companies, medical-device manufacturers, chemical companies, and supplement producers. These environments share needs for governed quality, records, documents, change, CAPA, risk, suppliers, training, approvals, and audit trails. Yet their terminology, regulations, validation expectations, data-integrity controls, and product lifecycles differ significantly. They will not be treated as a relabeled version of the food and beverage solution.
The current platform provides a general foundation for many quality operations, but suitability for a new regulated sector requires detailed gap analysis, industry-specific terminology, data models, workflows, controls, current requirement mapping, security, documentation, and validation testing. QSigma360 is therefore not currently a compliant, validated, or production-ready package for a particular pharmaceutical, medical-device, cosmetics, chemical, or supplement environment.
The roadmap may adapt versioning, review, approval, distribution, archival, and audit trails to each industry. Record, signature, retention, data-integrity, and validation requirements must be defined and verified. These controls are not currently claimed as a complete pharmaceutical package.
The shared foundation can support investigation, action, and change, but target expansion needs sector-specific change types, impact assessments, reviews, dependencies, validation evidence, and approval routes appropriate to each product, process, and regulatory environment.
The roadmap may cover suppliers, materials, parts, service providers, assessments, risk, and connected quality events using controls adapted for medicines, devices, cosmetics, chemicals, or supplements. Complete external portals and industry templates are not ready for these uses today.
Expansion may require sector-specific risk registers, assessment methods, training, competence, and validation evidence. Standalone enterprise Risk Management and Training modules remain on the roadmap, and their current related elements do not constitute a complete regulated-industry system.
Later phases may develop terminology, forms, workflows, reports, dashboards, and requirement maps that differ across pharmaceuticals, cosmetics, devices, chemicals, and supplements. A complete or approved library of industry templates does not exist today.
Future AI capabilities may support drafting, classification, investigation questions, and summarization within approved sources and permissions. AI will not approve a record, sign, close CAPA, authorize change, or issue regulatory judgment. Every use requires risk assessment and human review.
QSigma360 currently provides a foundation across nonconformance and complaints, CAPA, Change Control, Document Control, Supplier Quality, Audits, reporting, and governed AI, with status and configuration varying by module. That foundation is an engineering starting point, not evidence of industry suitability. Each sector still needs data models, terminology, requirements, controls, validation tests, implementation planning, and specialist support before a credible commercial release.
Industry-expansion initiatives are a flexible roadmap, not contractual commitments unless a separate agreement defines scope, stages, deliverables, schedule, and acceptance criteria. No ready industry demonstration, compliance, validation, or certification claim is made. Any early engagement is requirements discovery and fit assessment only, with protected information, appropriate access, and legal, regulatory, and technical review before development or use.
Discover need: Work with industry experts to understand processes, roles, terminology, and risks.
Analyze gaps: Compare the current foundation with regulatory, quality, data, and validation needs.
Approve product scope: Define what will and will not be built, with ownership and acceptance criteria.
Design industry configuration: Develop required data structures, workflows, templates, permissions, and controls.
Test and validate: Complete security, functional, and industry review, document results, and resolve gaps.
Release under control: Begin with an approved limited deployment, monitor use, and expand without unsubstantiated promises.
No. The architecture is extensible, but no complete, validated, production-ready industry package is currently available for these sectors.
No complete or approved template library is announced for these industries. Development requires specialist requirements analysis, design, review, and testing.
There is no demo-ready industry product today. Organizations may talk to the team to share needs and contribute to future-roadmap discovery.
No. Priorities depend on market demand, research, experience, feasibility, and technical and regulatory review. A date or scope becomes binding only through a separate formal agreement.
If you work in pharmaceuticals, cosmetics, medical devices, chemicals, or supplements, share your processes, controls, and gaps with the QSigma360 team through a non-binding discovery conversation.
Start with a tailored demo built around your organization’s needs.
